Singapore, Feb. 21 -- Singapore-based biopharmaceutical companySpecialised Therapeutics (ST) has received the registration of YORVIPATH(palopegteriparatide) by the Therapeutic Goods Administration (TGA), for the treatment of chronic hypoparathyroidism in adults.

YORVIPATH was granted an Orphan Drug Designation and assessed through the TGA's Priority Review pathway.It is the first and only medicine to be listed on the Australian Register of Therapeutic Goods (ARTG) for the treatment of chronic hypoparathyroidism.

YORVIPATH is a first-in-class PTH replacement therapy. A prodrug of parathyroid hormone (PTH [1-34]), YORVIPATH is administered subcutaneously once daily, with sustained release of active PTH designed to provide PTH levels in th...